Gilead blew past top and bottom line expectations on the strength of strong sales for its hepatitis C treatments.» Read More
The FDA approved the use of Vertex Pharmaceuticals' Orkambi, a drug aimed to treat patients with cystic fibrosis.
The actor denounced new vaccination rules in California, but insists he is not anti-vaccine.
Hans Bishop, Juno Therapeutics CEO, discusses the company's strategic collaboration with Celgene to develop advance immunotherapies for patients with cancer and autoimmune diseases.
Biotech giant Celgene has invested $1 billion in Juno Therapeutics in a move to that backs experimental cancer treatments, the FT reports.
Chart analyst John Kosar explains how to trade two stocks, he believes, are at key inflection points.
Options expert Dan Nathan explains how one trader made $144,000 on Zoetis deal chatter in a matter of minutes.
Jim Cramer says Finish Line posted a winning quarter and Alder Biopharma will determine the face of biotech.
Arie Belldegrun, Kite Pharma CEO, discusses the future of immunotherapy and its collaboration to develop cancer T-cell therapies.
CNBC's Meg Tirrell takes a look at what's driving shares of Kite Pharma higher, as the biotech company announces it is joining forces with Bluebird to collaborate on cancer T-cell therapies.
Automatic generic-drug substitution poses several big problems, says NYU Professor Melissa Schilling.
The CEO of Medtronic talks new FDA approval and how to improve the health-care system.
Steve Rusckowski, Quest Diagnostics CEO, sits down with CNBC's Meg Tirrell for an exclusive interview.
CNBC's Meg Tirrell sits down with Michael Mahoney, Boston Scientific CEO, for an exclusive interview.
CNBC's Meg Tirrell sits down with Omar Ishrak, Medtronic CEO, for an exclusive interview to discuss the company's product pipeline and business strategy.
Chart analyst John Kosar explains why biotech stocks have further to run, despite recent weakness.
Johnson & Johnson has established a microbiome institute to focus on developing treatments aimed at restoring the balance of micro-organisms. Details, with CNBC's Meg Tirrell.
CNBC's Morgan Brennan finds bargains in the outperforming biotech sector.
Biotech is going to break out, RBC Capital Markets' Michael Yee said. There are the names on his buy list.
Michael Yee, RBC Capital Markets, biotech analyst, discusses growth to come in the biotech sector and forecasts if the all-time highs will continue. Also, which stocks to own in the space.
CNBC's Meg Tirrell explains what the microbiome is and why it's medicines new frontier.
Get the best of CNBC in your inbox